Bernstein analyst Lance Wilkes downgraded Agilon Health (AGL) to Market Perform from Outperform with a price target of $1.40, down from $4. The firm cites the company’s worse than expected margin pressure for the downgrade. Agilon’s margin challenges reduce its capital cushion and increases its cost of capital, which creates an uncertain growth outlook, the analyst tells investors in a research note. Bernstein does not see the company as representing a strategically valuable asset that could be attractive to buyers.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
- Agilon Health price target lowered to $1.10 from $2.40 at Jefferies
- Agilon Health price target lowered to $1 from $5 at Baird
- Agilon Health’s Earnings Call: Challenges and Optimism
- Agilon Health Faces Uncertainty Amid RAF Challenges and Leadership Changes